Bristol Myers Squibb Company $BMY Shares Sold by Cary Street Partners Financial LLC

Cary Street Partners Financial LLC lowered its position in shares of Bristol Myers Squibb Company (NYSE:BMY) by 31.0% in the fourth quarter, Holdings Channel reports. The institutional investor owned 73,395 shares of the biopharmaceutical company’s stock after selling 33,050 shares during the quarter. Cary Street Partners Financial LLC’s holdings in Bristol Myers Squibb were worth $3,959,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. increased its holdings in Bristol Myers Squibb by 1.4% in the 4th quarter. Vanguard Group Inc. now owns 198,727,768 shares of the biopharmaceutical company’s stock valued at $10,719,376,000 after purchasing an additional 2,743,759 shares during the last quarter. State Street Corp increased its holdings in Bristol Myers Squibb by 2.0% in the 3rd quarter. State Street Corp now owns 96,595,232 shares of the biopharmaceutical company’s stock valued at $4,356,445,000 after purchasing an additional 1,855,238 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in Bristol Myers Squibb by 11.5% in the 3rd quarter. Dimensional Fund Advisors LP now owns 18,143,672 shares of the biopharmaceutical company’s stock valued at $818,105,000 after purchasing an additional 1,873,618 shares during the last quarter. Pzena Investment Management LLC increased its holdings in Bristol Myers Squibb by 20.4% in the 4th quarter. Pzena Investment Management LLC now owns 17,943,503 shares of the biopharmaceutical company’s stock valued at $967,873,000 after purchasing an additional 3,041,899 shares during the last quarter. Finally, Legal & General Group Plc increased its holdings in Bristol Myers Squibb by 1.7% in the 4th quarter. Legal & General Group Plc now owns 17,366,032 shares of the biopharmaceutical company’s stock valued at $936,724,000 after purchasing an additional 290,289 shares during the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.

Analyst Ratings Changes

BMY has been the subject of several research reports. HSBC lifted their target price on shares of Bristol Myers Squibb from $53.00 to $60.00 and gave the company a “hold” rating in a report on Tuesday, March 17th. Barclays initiated coverage on shares of Bristol Myers Squibb in a report on Thursday, February 19th. They issued an “overweight” rating and a $75.00 target price for the company. Weiss Ratings reissued a “hold (c)” rating on shares of Bristol Myers Squibb in a research report on Monday, March 23rd. Cantor Fitzgerald raised their price target on shares of Bristol Myers Squibb from $45.00 to $54.00 and gave the company a “neutral” rating in a research report on Wednesday, April 8th. Finally, UBS Group reissued a “buy” rating and issued a $70.00 price target on shares of Bristol Myers Squibb in a research report on Friday, March 6th. Eight research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Bristol Myers Squibb has a consensus rating of “Hold” and a consensus target price of $61.31.

Insider Activity

In other news, EVP David V. Elkins sold 30,000 shares of Bristol Myers Squibb stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the completion of the sale, the executive vice president directly owned 159,248 shares of the company’s stock, valued at approximately $9,820,824.16. The trade was a 15.85% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.05% of the company’s stock.

Bristol Myers Squibb Stock Performance

Shares of BMY stock opened at $58.19 on Wednesday. The company has a quick ratio of 1.28, a current ratio of 1.42 and a debt-to-equity ratio of 2.10. Bristol Myers Squibb Company has a 52 week low of $42.52 and a 52 week high of $62.89. The stock has a market capitalization of $118.83 billion, a PE ratio of 16.35, a P/E/G ratio of 0.17 and a beta of 0.26. The firm has a 50 day moving average of $58.46 and a two-hundred day moving average of $56.11.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 EPS for the quarter, beating the consensus estimate of $1.42 by $0.16. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The company had revenue of $11.49 billion during the quarter, compared to analysts’ expectations of $10.93 billion. During the same quarter last year, the company posted $1.80 EPS. The firm’s revenue was up 2.6% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, research analysts predict that Bristol Myers Squibb Company will post 6.31 EPS for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, May 1st. Stockholders of record on Thursday, April 2nd were given a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 4.3%. The ex-dividend date of this dividend was Thursday, April 2nd. Bristol Myers Squibb’s payout ratio is 70.79%.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.